Testosterone replacement therapy in hypogonadal men and prostate cancer risk

BJU International

Volumn 96, Issue 4, 2005, Pages 471-472

  Kirby, Roger ^a   Gould, Duncan ^a,b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b 20 Harmont House ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

AGE; AGING; ANDROGEN DEFICIENCY; ANDROPAUSE; CANCER RISK; DIETARY INTAKE; DRUG USE; ENVIRONMENTAL FACTOR; GENETIC RISK; GENETIC SUSCEPTIBILITY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LIFESTYLE; MALE; NOTE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; TESTOSTERONE BLOOD LEVEL; UNITED KINGDOM;

ADULT; AGED; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TESTOSTERONE;

EID: 24044473720     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05665.x     Document Type: Note

References (11)

1. Morales A, Lunenfeld B. Standards, guidelines and recommendations of the International Society for the Study of the Aging Male (ISSAM). Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. Aging Male 2002; 5: 74-86
2. Bostwick DG, Burke HB, Djakiew D et al. Human prostate cancer risk factors. Cancer 2004; 101: 2371-490
3. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB. The role of inflammation in the pathogenesis of prostate cancer. J Urol 2004; 172: S6-12
4. Rhoden EL, Morgentaler A. Risks of testosterone replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482-92
5. Slater S, Oliver RTD. Testosterone, its role in the development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 2000; 17: 431-9
6. Carter HB, Pearson JD, Metter EJ et al. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 1995; 27: 25-31
7. Heikkila R, Aho K, Heliovaara M et al. Serum testosterone and sex hormone binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 1999; 86: 312-5
8. Hsing AW. Hormones and prostate cancer: what's next? Epidemiol Rev 2001; 23: 42-58
9. Hoffman MA, DeWolf WC, Morgentaler A. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000; 163: 824-7
10. Maderbacher S, Schalzl G, Bieglmayer C et al. Impact of radical prostatectomy and TURP on the hypothalamo-pituitary-gonadal hormone axis. Urology 2002; 60: 869-74
11. Morgentaler A, Bruning CO III, De Wolf WC. Occult prostate cancer in men with low serum testosterone levels. JAMA 1996; 276: 1904-6